The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative analysis of different maintenance regimens after first-line induction in patients with metastatic colorectal cancer.
 
AMR Mohamed
No Relationships to Disclose
 
Nadine Abdallah
No Relationships to Disclose
 
Hibah Ismail
No Relationships to Disclose
 
Wei Chen
No Relationships to Disclose
 
Hyejeong Jang
No Relationships to Disclose
 
Daryn W. Smith
No Relationships to Disclose
 
Alaa Akhras
No Relationships to Disclose
 
Anteneh A. Tesfaye
No Relationships to Disclose
 
Philip Agop Philip
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Merrimack; Novartis; Roche; Sanofi
Consulting or Advisory Role - Celgene; Gilead Sciences; Halozyme; Ipsen; Merrimack; novartis
Speakers' Bureau - amgen; Bayer; Celgene; roche; sanofi
Research Funding - Bayer (Inst); Genentech (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - Celgene; emd serono; Halozyme; Roche; sanofi
 
Anthony Frank Shields
Employment - Benchling (I)
Stock and Other Ownership Interests - Benchling (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Endocyte; GE Healthcare; Merck; Merrimack; Personal Genome Diagnostics; Siemens Healthcare Diagnostics; Taiho Pharmaceutical
Speakers' Bureau - GE Healthcare
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eisai; H3 Biomedicine; Inovio Pharmaceuticals; Karyopharm Therapeutics; Merrimack; Novartis; OncoMed; Plexxikon; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Caris Life Sciences; Endocyte; GE Healthcare; Merrimack